Best Healthcare Equipment Stocks To Own Right Now

Traders participate in the financial markets through the frequent buying and selling of stocks, futures, forex and other securities, and are often categorized into two broad groups: discretionary and system. Discretionary traders are decision-based traders who scan the markets and place manual orders in response to information that is available at that time. System traders, in contrast, are rules-based traders who use some level of automation to employ an objective set of rules, allowing a computer to both scan for trading opportunities and handle the order entry activity. Here, we explain system trading and describe a typical day in the life of a system trader.

System Trading
System traders either employ proprietary black box trading strategies, or design and test their own systems that are designed to execute trades automatically. Black box systems utilize pre-programmed logic to generate and act upon buy and sell signals. Users cannot view the system's code, but do have access to historical performance reports and may be able to adjust certain inputs to fine tune the product. High frequency traders (HFT), who today account for about half of stock trades in the U.S., are system traders who employ sophisticated automated trading systems to exploit market inefficiencies and place hundreds of trades each session.

Best Healthcare Equipment Stocks To Own Right Now: Roche Holding AG (RHHBY)

Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.

During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.

In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.

Pharmaceuticals

Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.

Diagnostics

Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.

Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.

Advisors' Opinion:

• [By James E. Brumley]

  Look out Roche Holding Ltd. (OTCMKTS:RHHBY), and Opko Health Inc. (NYSE:OPK) - you're on notice too. There's a new player in the human growth hormone arena, and it may have built the proverbial better mousetrap. Versartis Inc. (NASDAQ:VSAR) only went public in late March, but with the dust from that IPO settling, it's already becoming clear that VSAR - admittedly a one-trick pony - could pose a real threat to OPK and RHHBY... at least on the human growth hormone front.

• [By George Budwell]

  Inovio Pharmaceuticals (NYSEMKT: INO  ) develops DNA-based vaccines and delivers them using a proprietary electroporation technique. Shares of Inovio have been a roller coaster all year long, and have certainly been the playground of day traders. Last week, Inovio shares lost more than 10% of their value on heavy volume, suggesting the stock may continue to experience downward pressure. This rapid move downward is surprising because the company recently signed a licensing deal with Roche (NASDAQOTH: RHHBY  ) to commercialize Inovio's multi-antigen DNA immunotherapies for prostate cancer and hepatitis B. As part of the deal, Inovio received $10 million upfront, and milestone payments could go as high as $412 million.

• [By Dan Carroll]

  First off, the melanoma drug market isn't huge -- yet. Research firm Decision Resources said last year that Roche's (NASDAQOTH: RHHBY  ) Zelboraf and Bristol-Myers Squibb's (NYSE: BMY  ) Yervoy, two immunotherapies approved in 2011 to treat melanoma, accounted for two-thirds of the malignant melanoma drug market. Yervoy picked up more than $700 million in sales last year, but Zelboraf only recorded around $250 million in revenue. That's not a giant market to capitalize on.

• [By Sean Williams]

  So what: It's been a miserable day for Allergan, which started the day off by slightly lowering its full-year EPS forecast from a range of $4.75-$4.83 to $4.70-$4.76. To add the icing on the cake, its midday report that DARPin did show some differentiation from Novartis (NYSE: NVS  ) and Roche's (NASDAQOTH: RHHBY  ) Lucentis but didn't demonstrate enough to move the drug onto phase 3 trials, sent Allergan into the abyss. It probably doesn't help, either, that MAP's inhaled migraine drug Levadex, which Allergan acquired when it purchased MAP for nearly $1 billion earlier this year, also recently received its second complete response letter. Allergan just can't seem to catch a break.

Best Healthcare Equipment Stocks To Own Right Now: NN Inc.(NNBR)

NN, Inc. engages in the manufacture and sale of metal bearing, plastic and rubber, and precision metal components for bearing manufacturers worldwide. It operates in three segments: Metal Bearing Components, Plastic and Rubber Components, and Precision Metal Components. The Metal Bearing Components segment manufactures precision steel balls that are used primarily by manufacturers of anti-friction bearings; steel rollers comprising tapered rollers used in automotive gearbox applications, automotive wheel bearings, and various industrial applications; cylindrical rollers; and precision metal retainers for roller bearings. The Plastic and Rubber Components segment offers precision bearing seals for use in the automotive, industrial, agricultural, and mining markets; precision plastic retainers for ball and roller bearings used in various industrial applications; and precision plastic components, including automotive under-the-hood components, electronic instrument cases, pre cision electronic connectors and lenses, and various specialized industrial and consumer parts. The Precision Metal Components segment provides engineered shafts, fluid power assemblies, and complex precision assembled and tested parts used in the automotive, HVAC, fluid power, and diesel engine markets. The company was founded in 1980 and is based in Johnson City, Tennessee.

Advisors' Opinion:

• [By Eric Volkman]

  NN (NASDAQ: NNBR  ) has a new man in the CEO chair. Richard Holder has been tapped to be the firm's CEO, effective June 3. He replaces the retiring Roderick Baty. Holder will also assume Baty's board seat, the term for which runs through NN's annual meeting in 2015.

Top 10 Stocks To Watch Right Now: Blackrock Global (BOE)

BlackRock Global Opportunities Equity Trust is a closed ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets across the globe. The fund invests in the stocks of companies operating across diversified sectors. It primarily invests in all cap companies. The fund benchmarks the performance of its portfolio against the S&P Global Broad Market Index. BlackRock Global Opportunities Equity Trust was formed on May 31, 2005 and is domiciled in the United States.

Advisors' Opinion:

• [By Robert Rapier]

  Whiting Petroleum (WLL) is one of Continental's biggest competitors in the Bakken. Whiting is the second-largest oil producer in North Dakota, averaging 82,500 barrels of oil equivalent (BOE) of production in 2012, across more than 700,000 acres of leased land.

• [By idahansen]

  Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.

• [By Fede Zaldua]

  Even when production was down by 2%, realization prices were up by 4% at $67.4 per barrel of oil equivalent (boe). Downstream was, by far, the weakest link of all. Downstream earnings declined aggressively by 76% year over year due to lower margins and the sale of two refineries in the U.S. As a matter of fact, earnings were 74% upstream, 14% Rosneft and 12% downstream. Earnings were good but they are still a reflection of a company that is trying to reshape itself.

Best Healthcare Equipment Stocks To Own Right Now: Natural Gas(NG)

NovaGold Resources Inc., through its subsidiaries, engages in the exploration and development of mineral properties primarily in North America. The company primarily explores for gold, silver, copper, zinc, and lead ores. It holds interests in the Donlin Creek property covering 81,361 acres and the Ambler property comprising 90,614 acres located in Alaska; and the Galore Creek property comprising 293,838 acres located in northwestern British Columbia, Canada. The company was formerly known as NovaCan Mining Resources (1985) Limited and changed its name to NovaGold Resources Inc. in March 1987. NovaGold Resources Inc. was founded in 1984 and is based in Vancouver, Canada.

Advisors' Opinion:

• [By Dan Caplinger]

  NovaGold Resources (NYSEMKT: NG  ) will give investors its quarterly report on Wednesday. But the mining company has already seen its stock plunge in the wake of crashing gold prices, and NovaGold earnings results aren't likely to give investors much good news barring a big surprise.

• [By Monica Gerson]

  NovaGold Resources (NYSE: NG) is expected to post a Q3 loss at $0.03 per share.

  Premier Exhibitions (NASDAQ: PRXI) is projected to post its Q2 earnings.

Best Healthcare Equipment Stocks To Own Right Now: The Pantry Inc.(PTRY)

The Pantry, Inc. operates a chain of convenience stores in the southeastern United States. The company?s stores offer a selection of merchandise, fuel, and ancillary products and services. Its merchandise products include cigarettes, grocery and other tobacco products, packaged beverages, beer, and wine. The company operates stores under various selected banners, which primarily include Kangaroo Express. As of September 29, 2011, it operated 1,649 convenience stores located in Florida, North Carolina, South Carolina, Georgia, Alabama, Tennessee, Mississippi, Virginia, Kansas, Kentucky, Louisiana, Indiana, and Missouri; and 233 quick service restaurants. The company was founded in 1967 and is headquartered in Cary, North Carolina.

Advisors' Opinion:

• [By Geoff Gannon]

  For one thing, I can�� tell a great oil company from a not so great oil company. I can�� evaluate the company�� culture, management, etc. There was no way I was ever going to answer questions like that. But I can easily split Murphy�� U.S. retail business from its other operations. And I can compare that part of the company to other public companies like Pantry (PTRY) and Susser (SUSS). I can also ��this is much harder ��look at Murphy�� reserves and compare them to other oil companies��reserves. The SEC now requires a standardized way of reporting discounted net cash flows for all oil companies. So, there�� certainly a specific number available for every company. Whether it�� a very good number or not depends on the assumptions the method uses.

Best Healthcare Equipment Stocks To Own Right Now: Netflix Inc.(NFLX)

Netflix, Inc. provides Internet subscription services for TV shows and movies in the United States and internationally. The company offers its subscribers to watch unlimited TV shows and movies streamed over the Internet to their TVs, computers, and mobile devices. It also provides standard definition DVDs and Blu-ray discs to its subscribers. The company was founded in 1997 and is headquartered in Los Gatos, California.

Advisors' Opinion:

• [By MONEYMORNING]

  At this year's CES, none other than tech giant Netflix Inc. (Nasdaq: NFLX) put its support behind 4K technology.

  This is a big deal - for one good reason.

• [By Daniel Sparks]

  Netflix (NASDAQ: NFLX  ) has sold off significantly recently, falling from a 52-week high this month of almost $250 a share. Is this a chance to jump in and buy shares, or is this a correction after an overzealous run-up? In the video below, Fool contributor Daniel Sparks weighs in.

• [By Anders Bylund]

  CEO Reed Hastings is not an iron-fisted dictator at Netflix� (NASDAQ: NFLX  ) . In particular, I'd imagine that Hastings would have an increasingly hard time doing his job without longtime lieutenant Ted Sarandos.

Best Healthcare Equipment Stocks To Own Right Now: Insteel Industries Inc.(IIIN)

Insteel Industries, Inc. manufactures and markets steel wire reinforcing products for concrete construction applications. The company offers pre-stressed concrete strand (PC strand) and welded wire reinforcement (WWR) products. Its PC strand is a high strength seven-wire strand that is used to impart compression forces into precast concrete elements and structures, which may be either pre-tensioned or post-tensioned, providing reinforcement for bridges, parking decks, buildings, and other concrete structures. The company?s WWR is produced as either a standard or a specially engineered reinforcing product for use in nonresidential and residential construction. Its products comprise concrete pipe reinforcement, an engineered made-to-order product that is used as the primary reinforcement in concrete pipe, box culverts, and precast manholes for drainage and sewage systems, water treatment facilities, and other related applications; engineered structural mesh, an engineered m ade-to-order product, which is used as the primary reinforcement for concrete elements or structures; and standard welded wire reinforcement, a secondary reinforcing product for crack control applications in residential and light nonresidential construction, including driveways, sidewalks, and various slab-on-grade applications. Insteel Industries sells its products through sales representatives to the manufacturers of concrete products, distributors, and rebar fabricators in the United States, Canada, Mexico, and Central and South America. The company was founded in 1958 and is headquartered in Mount Airy, North Carolina.

Advisors' Opinion:

• [By Rich Duprey]

  With steely reserve,�Insteel Industries� (NASDAQ: IIIN  ) �declared it will pay a�quarterly cash dividend�of�$0.03 per share on June 28 to shareholders of record at the close of business on June 14.

• [By Seth Jayson]

  Insteel Industries (Nasdaq: IIIN  ) reported earnings on April 18. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended March 30 (Q2), Insteel Industries missed estimates on revenues and beat expectations on earnings per share.

• [By Seth Jayson]

  Insteel Industries (Nasdaq: IIIN  ) reported earnings on July 18. Here are the numbers you need to know.

  The 10-second takeaway
  For the quarter ended June 29 (Q3), Insteel Industries met expectations on revenues and missed estimates on earnings per share.